MIT and UCSB Researchers Develop Light-Activated Platform to Discover Broad-Spectrum Antiviral Compounds
核心洞察
Researchers from MIT and UC Santa Barbara (搜索) developed an innovative optogenetic platform that uses light to identify compounds capable of enhancing the integrated stress response (搜索) (ISR (搜索)) pathway for broad-spectrum antiviral activity.
The high-throughput screening of 370,830 compounds led to the discovery of nearly 3,500 potential antiviral agents, with three lead candidates (IBX-200 (搜索), IBX-202 (搜索), and IBX-204 (搜索)) showing significant activity against Zika virus (搜索), herpes (搜索), and RSV (搜索).
The compounds work by amplifying the host cell's natural stress response to viral infection, causing infected cells to undergo programmed death while leaving healthy cells unaffected.
Researchers from the Massachusetts Institute of Technology (MIT) and UC Santa Barbara (搜索) have developed a groundbreaking optogenetic platform that identifies compounds capable of enhancing the body's natural antiviral defenses. The innovative approach, published in the journal Cell, led to the discovery of broad-spectrum antiviral compounds effective against multiple viruses including Zika virus (搜索), herpes (搜索), and respiratory syncytial virus (搜索) (RSV (搜索)).
Revolutionary Optogenetic Screening Platform
The research team, led by James Collins from MIT's Institute for Medical Engineering and Science and Max Wilson from UC Santa Barbara (搜索), created a novel drug discovery platform that uses light to simulate viral stress without actually damaging cells. This "virtual stress" approach allows researchers to study the integrated stress response (搜索) (ISR (搜索)) pathway in isolation, overcoming a major challenge in stress response research.
"We're very excited about this work, which allows us to harness the stress response of the host cells to arrive at a means to identify and develop broad-spectrum antivirals," said Collins in a news release.
The platform utilizes light-induced clustering of protein PKR (搜索), which triggers ISR (搜索)-mediated cell death. This innovative approach enabled high-throughput screening of 370,830 compounds to identify potential therapeutic agents that could modulate the host cell stress response.
Targeting the Integrated Stress Response
When human cells encounter viral infections, they activate the integrated stress response (搜索) pathway as a protective mechanism. This pathway is specifically initiated by the detection of double-stranded RNA (搜索) (dsRNA (搜索)), a molecule that viruses generate during replication. Upon sensing dsRNA, cells halt protein synthesis, preventing viruses from manufacturing essential proteins required for reproduction.
"Any normal environmental stress that you put on cells activates several pathways simultaneously, and so it's very hard to study one stress response at a time," explained Wilson. The optogenetic platform overcomes this limitation by creating targeted stress responses without cellular damage.
Promising Compound Discovery
The initial screening resulted in approximately 300 "shortlisted" compounds that selectively potentiate cell death in infected cells. Further evaluation identified nearly 3,500 compounds with potential antiviral activity. Among the most promising candidates, researchers focused on eight compounds for detailed analysis, ultimately selecting three lead candidates: IBX-200 (搜索), IBX-202 (搜索), and IBX-204 (搜索).
These compounds demonstrated significant antiviral activity by substantially reducing viral load in human cells infected with Zika virus (搜索), herpes zoster (搜索), and RSV (搜索). The compounds work by activating a key enzyme involved in stress detection, which triggers the broader stress response pathway and makes cells more resilient to viral infection.
Mechanism of Action and Selectivity
The newly identified compounds exhibit a targeted effect, showing no impact on uninfected cells. Felix Wong, former MIT postdoc and CEO of Integrated Biosciences (搜索), explained the mechanism: "If the pathway were turned on in response to viral infection, what our compounds do is they turn it on full blast. Even in the presence of a small amount of virus, if the pathway is triggered, then the antiviral response is also maximized."
This approach represents a departure from traditional antiviral development. "Typically, how antivirals are developed is that you develop one antiviral for one specific virus," Wong noted. "In this case, we hypothesized that being able to modulate the host cell stress response might give us a new class of broad-spectrum antivirals—compounds that directly act on the host cells to alter something fundamental about how all viruses replicate."
In Vivo Validation
The research team successfully demonstrated the compounds' efficacy in vivo using a mouse model of ocular herpes (搜索). IBX-200 (搜索) was able to reduce viral load and improve symptoms associated with the virus, providing crucial proof-of-concept for the therapeutic potential of these host-directed antivirals.
"We ended up testing them on Zika, and they worked. RSV (搜索): they worked. Herpes (搜索): they worked. And they worked almost as well as the state-of-the-art treatment, but they were completely unoptimized. So it's very promising," said Wilson.
Clinical Development Pathway
The compounds are now undergoing further evaluation as the research team plans to test them against additional viruses to develop them for future clinical trials. The approach holds particular promise for pandemic preparedness, as these host-directed antivirals could potentially work against novel viral threats without requiring virus-specific development.
Wilson emphasized the broader implications: "I came to the conclusion that probably the only thing that has a really good chance of working would be host-directed pan-antivirals, because you don't know what the virus is until too late and it takes too long to make a vaccine. So we need just molecules that people can take that make us just generally better at fighting infections."
Expanding Applications
Beyond antiviral applications, the optogenetic platform shows promise for addressing age-related diseases. The Wilson Lab is now using this technology to discover compounds that can help with healthy aging, as aging affects ISR (搜索) pathways and could contribute to adult-onset diabetes, neurodegenerative disorders, and cancers.
"I think we are only scratching the surface of what optogenetics can achieve in drug discovery," Wilson added. "We are excited to see if we can use this new approach to bring transformative treatments all the way to the clinic. That's the dream."